Ovid Therapeutics (OVID) Income towards Parent Company (2016 - 2026)

Ovid Therapeutics has reported Income towards Parent Company for 11 years, with the latest figure at -$17.0 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company fell 65.98% year-over-year to -$17.0 million; the trailing twelve-month figure through Mar 2026 stood at -$24.2 million (up 3.23% YoY), and the FY2025 full-year result was -$17.4 million, up 34.12% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$17.0 million, down from $9.7 million in the prior quarter.
• The five-year high for Income towards Parent Company was $9.7 million in Q4 2025, with the low at -$17.0 million in Q1 2026.
• Historically, Income towards Parent Company has averaged -$9.8 million across 5 years, with a median of -$12.0 million in 2022.
• The largest YoY upside for Income towards Parent Company was 204.43% in 2025 against a maximum downside of 154.97% in 2025.
• Ovid Therapeutics' Income towards Parent Company stood at -$11.5 million in 2022, then sank by 33.18% to -$15.3 million in 2023, then soared by 39.61% to -$9.3 million in 2024, then soared by 204.43% to $9.7 million in 2025, then slumped by 275.8% to -$17.0 million in 2026.
• The last three Income towards Parent Company figures came in at -$17.0 million (Q1 2026), $9.7 million (Q4 2025), and -$12.2 million (Q3 2025), per Business Quant data.